Search

Provider-listed inquiry route. Checked 2026-10-05. Separate from Eliava Phage Therapy Center (EPTC). The clinic describes individualized bacterial-infection assessment and outpatient phage treatment in Tbilisi; contact the clinic to confirm

Status unconfirmed. Checked 2026-10-03. Nonprofit advocacy, clinician network and access support; no directly treating service established. United Kingdom facilitator GB Patient and carer enquiries have been listed at admin@phageuk.org. The

Research/development. Checked 2026-10-03. Inhaled phage development for P. aeruginosa; PHAGE4CURE-001 healthy-volunteer study completed September 2023 to May 2025. Berlin; Braunschweig; Hannover; Germany research-only DE Research project ne

Research/development. Checked 2026-10-03. Site describes a specialty-pharmaceutical company established in 2025 with S. aureus, E. coli and P. aeruginosa phage portfolios. Lyon; France company FR Current corporate/health-professional contac

Historical/inactive. Checked 2026-10-03. P. aeruginosa/E. coli burn-wound phage development; multinational burn-unit study. France; Belgium; Switzerland research-only BE CH FR Historical trial/project, not a current patient access route.

Historical/inactive. Checked 2026-10-03. Synthetic lysin antibacterial development; not established as a current live-phage clinic. Vienna; Austria company AT Former independent company was acquired by BioNTech in 2021; no current independe

Historical/inactive. Checked 2026-10-03. Historical S. aureus, E. coli and P. aeruginosa clinical phage development, including prosthetic joint infection and burn trials. Lyon / historical Nantes activity; France company FR PHAXIAM announce

Provider-listed inquiry route. Checked 2026-10-03. Current site describes phage-containing dietary supplements for microbial balance and hygiene products, rather than an established clinical infection-treatment service. Ukraine supplier UA

Active program; intake unconfirmed. Checked 2026-10-03. Phage research, characterization and clinical supply expertise associated with the military hospital. Brussels (Neder-over-Heembeek); Belgium supplier BE Official hospital laboratory p

Official referral/inquiry route. Checked 2026-10-03. Severe or chronic resistant/biofilm/implant-related infections after alternatives are exhausted; matching, characterization and individual compassionate treatment. Regensburg; Germany tre

Research/development. Checked 2026-10-04. Research project on phage therapy and microbiome restoration for recurrent urinary tract infections. The project describes a Phase Ib/IIa randomized study. Coordinated in Frankfurt, Germany; Europea

Intake unconfirmed. Checked 2026-10-03. Randomized phage-plus-antibiotic treatment study for infective endocarditis; planned enrollment 30. Moscow; Russia treating-center RU ClinicalTrials.gov gives study contacts and a recruiting Moscow fa

Research/development. Checked 2026-10-03. Phase 1b/2a IV engineered SASPject PT3.9 for adults aged 18–60 with CF-associated susceptible P. aeruginosa infection; projected first enrollment January 1, 2027. Cambridge (sponsor); Liverpool (pla

Provider-listed inquiry route. Checked 2026-10-03. Engineered CRISPR/phage programs; SNIPR001 targets E. coli, including hematologic malignancy/transplant infection-risk research. Copenhagen; Denmark company DK Official expanded-access requ

Provider-listed inquiry route. Checked 2026-10-03. TP-102 investigational topical phages for infected diabetic foot/nonhealing wounds involving S. aureus, P. aeruginosa or A. baumannii; separate TP-122 respiratory development. Lisbon; Portu

Status unconfirmed. Checked 2026-10-03. Clinical support and manufacturing/access coordination; not itself confirmed as a treating clinic. United Kingdom facilitator GB Describes phage-sourcing support for UK clinicians. The website was una

Official referral/inquiry route. Checked 2026-10-03. Selected severe bacterial infections after other options fail: chronic rhinosinusitis, bronchiectasis/CF respiratory infection, musculoskeletal infection and sepsis. Leuven; Belgium treat

Research/development. Checked 2026-10-03. 2026 research center using phage engineering, computational tools, susceptibility prediction and preclinical infection models. San Francisco, California; United States research-only US No patient in

Renamed Armata in 2019. Checked 2026-10-03. Historical phage-development company. company US Renamed Armata in 2019.

Acquired by AmpliPhi in 2011. Checked 2026-10-03. Historical phage-development company. company GB Acquired by AmpliPhi in 2011.